Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court Denies Pfizer Request To Halt Sales Of Ivax’ Neurontin Generic

This article was originally published in The Pink Sheet Daily

Executive Summary

A federal judge rejects Pfizer’s motion for a temporary restraining order and preliminary injunction to halt Ivax’ marketing of gabapentin tablets. Court rules that because Ivax’ generic is not AB-rated to Neurontin, Pfizer failed to establish irreparable harm.

You may also be interested in...



Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows

"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.

Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows

"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.

Pfizer Asks Court To Keep Purepac’s Neurontin Generic Off The Market

Brand company’s arguments in support of a preliminary injunction could be bolstered by the fact that, unlike Ivax’ product, Purepac’s gabapentin generic is AB-rated and the Alpharma division has said a launch would not hinge on resolution of patent litigation with Pfizer.

Topics

UsernamePublicRestriction

Register

PS060354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel